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Introduction
‘Zika fever’ was first reported in Uganda and Tanzania in
1952. Caused by the Zika flavivirus it consisted of a mild
and self-limiting illness of rash, low-grade fever, con-
junctivitis, headache and myalgia. Two strains of Zika
virus were subsequently identified (African and Asian)
with transmission via mosquito or sexual contact. Since
2007 there have been several epidemics of the Asian strain
including in French Polynesia (2013–2014; 20,000 cases)
and Brazil (2015–2016; 30,000 cases), and these outbreaks
have been associated with increased incidence of Guillain–
Barre´ syndrome (GBS) in adults and microcephaly in
infants.
Proving a causative link between an infectious agent and
subsequent neurological damage is not straightforward.
This month’s journal club examines three papers that
attempt to provide evidence connecting Zika virus to
neurological sequelae. The first is a case–control study of
GBS during the Zika virus epidemic in French Polynesia.
The second is a prospective cohort study reporting foetal
growth defects in pregnant women in Brazil, some of
whom had been infected with Zika virus. The third is a
cellular paper looking at neural expression of AXL, a
receptor that could mediate Zika virus entry into cells.
Guillain–Barre´ syndrome outbreak associated
with Zika virus infection in French Polynesia:
a case–control study
GBS is a rare condition that encompasses various forms of
acute immune-mediated polyradiculoneuropathy. It com-
monly presents as a monophasic, progressive symmetrical
weakness with depressed or absent reflexes, often after an
antecedent infection (Campylobacter jejuni gastroenteritis
being the most common). French Polynesia (population of
*270,000 in 2013) typically reports between three and ten
cases of GBS per year (i.e. 1–3 per 100,000), but during
4 months of the Zika epidemic (2013–2014) there were 42
cases (annualised incidence *45 per 100,000). This paper
compared these 42 consecutive GBS cases with two control
groups from the same hospital: first, patients with non-
febrile illness (n = 98); second, patients with confirmed
Zika virus infection but no neurological sequelae (n = 70).
Cases and controls were matched for age, sex, and island of
residence.
GBS cases showed a male preponderance (74 %) with a
median age of 42 years. Clinical characteristics included a
viral prodrome (88 % of cases), lag of 4–10 days between
viral syndrome and neurological symptoms, symmetric
muscle weakness (79 %), areflexia or hyporeflexia (48 %),
and facial palsy (79 %). Lumbar puncture showed
increased protein only (93 %). Nerve conduction studies
showed prolonged distal motor latencies (DMLs) and
reduced compound muscle action potential (CMAP)
amplitudes at diagnosis, with marked improvement at
3 months following treatment with intravenous
immunoglobulin. Sensory potentials were unaffected.
Clinical recovery was generally good (57 % walking
unaided at 3 months), although 38 % required intensive
care admission for ventilatory and/or nutritional support.
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Virological testing revealed IgM against Zika (i.e. evi-
dence of recent infection) in 93 % of GBS cases but just
17 % of non-febrile controls. However, there was no evi-
dence of acute viraemia in any of the cases, consistent with
patients rapidly clearing virus and being afebrile at pre-
sentation. Important negative serological tests included C.
jejuni, HIV, CMV, and EBV. No association was found
between previous dengue infection and GBS.
Comment. This paper shows a convincing correlation
between the Zika epidemic in French Polynesia and
increased incidence of GBS. The cases are consistent with
the acute motor axonal neuropathy (AMAN) subtype of
GBS, particularly the relatively preserved reflexes (52 %)
and rapid recovery. Zika virus may well be the causative
agent, but it is not possible to conclude this from a small
observational study. Another unidentified (and untested)
aetiological agent could exist. In addition, the controls
were suboptimal: control group 1 was selected from non-
febrile patients whereas 58 % of the GBS cases had fever
as part of a viral prodrome; control group 2 (acute Zika
infection) was not tested for Zika IgM/IgG nor followed up
to assess for neurological sequelae.
Cao-Lormeau V-M et al (2016) Lancet 387:1531–1539.
Zika virus infection in pregnant women in Rio de
Janeiro—preliminary report
Phylogenetic analyses suggest that Zika virus was intro-
duced to Brazil in late 2013. The first case was diagnosed
in May 2015, and an increase in neonatal microcephaly
identified in September 2015. To investigate a possible link
between Zika infection and foetal abnormalities, this
prospective cohort study recruited 88 pregnant women
(gestational age 5–38 weeks) who presented with a new
maculopapular rash during the epidemic of 2015. Seventy-
two patients (82 %) were Zika-positive and had non-
specific symptoms such as arthralgia, conjunctival injec-
tion, and pruritus. Standard pre-natal care in all 88 women
documented immunity to rubella and CMV, a negative
syphilis test, and positive dengue IgG (i.e. historical
infection) in 88 %. Foetal ultrasonography was abnormal
in 29 % Zika-positive women (n = 42), but normal in all
Zika-negative women tested (n = 16). Various foetal
abnormalities were observed including microcephaly (four
cases), intrauterine growth restriction (IUGR), cerebral
calcifications, oligohydramnios and cerebral blood flow
abnormalities. Microcephaly, where present, tended to be
part of a wider spectrum of neurodevelopmental problems.
There was no specific correlation between gestational age
at infection and foetal abnormalities. Interestingly, of the
six babies born so far following abnormal ultrasound scans
in utero, two have had microcephaly but in conjunction
(and proportion) to IUGR, and another has done well fol-
lowing anhydramnios.
Comment. This study adds some weight to the hypoth-
esis that Zika infection during pregnancy increases the risk
of a ‘congenital Zika syndrome’ consisting of micro-
cephaly and other neurodevelopmental problems. How-
ever, the study is incomplete (only 8 of 72 Zika-positive
pregnancies have been completed), the numbers are small
(particularly the control group), many Zika-positive
women refused ultrasonography (42 %), and other causes
of microcephaly have not been exhaustively investigated.
In particular, other causes of rash (the study’s inclusion
criterion) are not explored, and important possible con-
founding congenital infections such as acute dengue
(measured by IgM) or HIV are not documented. In addi-
tion, many of the Zika-positive women were from rural,
lower income areas, which could implicate other environ-
mental factors.
Brasil P et al (2016) NEJM. doi:10.1056/NEJMoa160
2412.
Expression analysis highlights AXL as a candidate
Zika virus entry receptor in neural stem cells
Zika virus can directly infect human cortical neural pro-
genitor cells in vitro, cause transcriptional dysregulation,
and attenuate cell growth. How Zika targets neural pro-
genitors is unknown. The authors postulate that selective
receptor expression in radial glia (neural stem cells of the
developing brain) could mediate Zika virus entry, making
these cells particularly susceptible to infection. Single-cell
RNA sequencing of foetal human cerebral cortex (gesta-
tional week 39) enabled typing by genome-wide expression
signatures, and assessment of putative Zika virus receptor
expression. Multiple possible entry receptor genes were
specifically enriched in radial glia, astrocytes, endothelial
cells, and microglia. In particular, AXL (previously shown
to mediate Zika and dengue virus entry into skin cells) was
more highly expressed in radial glia than other receptors.
Immunohistochemistry confirmed enrichment of AXL in
radial glia and developing human retinal cells when com-
pared to mature neurons. These expression patterns are
conserved in mice and ferrets, and can also be seen in
human iPSC-derived cerebral organoids suggesting model
systems to assay inhibitors of Zika cell entry. A
testable hypothesis that the neurotropism of the Zika virus
is mediated via AXL is proposed.
Comment. This preliminary paper shows that AXL and
numerous other putative Zika entry receptors are enriched
in various neural cell types, particularly stem cells. It does
not show any direct link between Zika virus and AXL, nor
does it exclude any of the other receptors as mediators of
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Zika entry. Further work is needed to investigate how (and
whether) AXL is involved in Zika neurotropism and stem
cell selectivity, and whether blocking cell entry is a rea-
sonable therapeutic avenue.
Nowakowski TJ et al (2016) Cell Stem Cell 18:1–6.
Conclusion. The timing of GBS a few days after Zika
virus infection, and the discovery of foetal abnormalities
following Zika infection in pregnancy similar to those seen
in gestational rubella or CMV infections seem to incrimi-
nate Zika virus as the aetiological agent. It is, however,
very difficult to prove a causative link, as these three
papers illustrate. However, whilst larger studies are con-
ducted a lack of scientific proof should not delay public
health measures to reduce risk—for example, use of mos-
quito nets and insect repellent. It should also be remem-
bered that even in the presence of Zika virus infection these
remain rare neurological events: the approximate risks of
GBS and microcephaly are 0.024 and 1 %, respectively.
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